Northern Lincolnshire and Goole NHS Foundation Trust

Specialist MDT: Hull University Teaching Hospitals NHS Trust

View Provider Services

Men diagnosed at this hospital trust can access the following services:

  • Diagnostic Facilities:
    • Multiparametric MRI
    • Transperineal biopsy under local anaesthetic
    • Transperineal biopsy under general anaesthetic
    • Transrectal ultrasound (TRUS) biopsy
    • Isotope bone scan
    • One-stop diagnostic clinic
  • Treatment Facilities:
    • Chemotherapy
  • Support Service Facilities:
    • Clinical Nurse Specialist (CNS) in all clinics
    • Advanced PCa CNS
    • Urology CNS
    • Specialist continence services

Data Quality

For Wales, this data completeness relates to patients diagnosed between April 2022 and March 2023.
For England, this data completeness relates to patients diagnosed in 2021. This is the data completeness of the National Cancer Registration Dataset (NCRD). For data completeness of the Rapid Cancer Registration Dataset (RCRD), please refer to the NPCA quarterly reports.

Diagnosing Trust Specialist MDT
No. of Cancer Registry records 260 1114
Performance Status recorded 58% 71%
PSA completed 97% 91%
Gleason Score completed 70% 74%
TNM completed 64% 80%

Disease Presentation

For Wales, these results relate to patients diagnosed between April 2022 and March 2023.
For England, these results relate to patients diagnosed between January and December 2021.

Specialist MDT National
No. of men with disease status determined 1065 39897
Percentage of men diagnosed with metastatic disease 21% 17%

Management

For Wales, these results relate to patients diagnosed between April 2022 and March 2023.
For England, these results relate to patients diagnosed between January and December 2021.

Specialist MDT National
No. of men diagnosed with low-risk localised disease 119 4684
Percentage of men with low-risk localised disease receiving radical treatment 4% 8%
No. of men diagnosed with locally advanced disease 509 15410
Percentage of men diagnosed with locally advanced disease receiving radical treatment 74% 68%